Power thrombectomy in acute ischemic coronary syndromes

Angiology

Volumn 54, Issue 4, 2003, Pages 457-468

  Topaz, On ^a   Perin, Emerson C ^c   Jesse, Robert L ^a   Mohanty, Pramod K ^a   Carr Jr , Marc ^a   Rosenschein, Uri ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EPTIFIBATIDE; FIBRIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLATELET RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; RETEPLASE; SODIUM CHLORIDE; STREPTOKINASE; THROMBIN; THROMBOCYTE RECEPTOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BALLOON DILATATION; BLEEDING; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DEVICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXCIMER LASER; FIBRINOLYSIS; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOLMIUM LASER; HUMAN; INTRACORONARY INFUSION; INTRAVASCULAR CATHETER; LOW DRUG DOSE; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POWER THROMBECTOMY; PULSED DYE LASER; RISK BENEFIT ANALYSIS; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBECTOMY; THROMBUS; ULTRASOUND; VASCULAR PATENCY;

EID: 0043168038     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970305400410     Document Type: Article

References (68)

1. Lefkovitz J, Topol EJ: Platelet inhibitor agents in ischemic heart disease. Update chapter #6. In: Textbook of Cardiovascular Medicine. Cedar Knolls, NJ: Lipincott Raven, 1998, pp 1-16.
2. Simes RJ, Topol EJ, Holmes DR, et al, for the GUSTO-1 Investigators: Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion. Circulation 91:1923-1928, 1995.
3. GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both, on coronary patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615-1622, 1993.
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results of all randomized trials of more than 1,000 patients. Lancet 343:311-322, 1994.
5. Anderson JL, Karagounis LA, Califf RA: Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 78:1-8, 1996.
6. Cannon CP: Overcoming thrombolytic resistance. J Am Coll Cardiol 34:1395-1402, 1999.
7. Bode C, Smalling RW, Berg G, et al, for the RAPID II Investigators: Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase and front-loaded, accelerated alteplase in patients with acute myocardial infarction. Circulation 94:891-898, 1996.
8. Cannon CP, McCabe CH, Gibson M, et al: TNK-Tissue plasminogen activator in acute myocardial infarction. Circulation 95:351-356, 1997.
9. Greilich PE, Carr ME, Zekert SL, et al: Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am J Med Sci 307:15-20, 1994.
10. Anderson JL: Why does thrombolysis fail? Breaking through the reperfusion ceiling. Am J Cardiol 80:1588-1590, 1997.
11. Carr ME, Hermans J: Site and density of very long fibers from turbidity-application of fibrin gels. Macromolecules 11:46-50, 1978.
12. Gabriel DA, Muga K, Boothroyd EM: The effect of fibrin structure on fibrinolysis. J Biol Chem 267:259-263, 1992.
13. Cannon CP, McCabe H, Diver DJ, et al: Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 24:1602-1610, 1994.
14. Verheugt FWA, Meijer A, Lagrand W, et al: Reocclusion: The flip side of coronary thrombolysis. J Am Coll Cardiol 27:766-773, 1996.
15. Ohman EM, Califf M, Topol EJ, et al: Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 82:781-791, 1990.
16. Brouwer MA, Bohncke JR, Veen G, et al: Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol 26:1440-1444, 1995.
17. The EPIC Investigators: Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 330:956-961, 1994.
18. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997.
19. The EPISTENT Investigators: Randomized placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352:87-92, 1998.
20. The IMPACT-II Investigators: Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 349:1422-1428, 1997.
21. The CAPTURE Investigators: Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 349:1429-1435, 1997.
22. The RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445-1453, 1997.
23. The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibative in patients with acute coronary syndromes. N Engl J Med 339:436-443, 1998.
24. The SPEED Investigators: Trial of abciximab with and without low-dose retephase for acute myocardial infarction. Circulation 101:278-2794, 2000.
25. Lincoff MA, Califf RM, Moliterno DJ, et al: Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 341:319-327, 1999.
26. Califf RM, Lincoff AM, Tcheng JE, et al: An overview of the results of the EPIC trial. Eur Heart J 16:43-49, 1995.
27. Silva JA: Editorial. Percutaneous coronary intervention of thrombotic lesions: Still challenging! Cathet Cardiovasc Intervent 56:8-9, 2002.
28. Singh M, Reeder GS, Ohman EM, et al: Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An angiographic trials pool data experience. J Am Coll Cardiol 38:624-630, 2001.
29. Zhao XQ, Theroux P, Snappin SM, et al: Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: Angiographic results from the PRISM-PLUS trial. Circulation 100:1609-1615, 1999.
30. Cura FA, L'Allier PL, Kapadia SR, et al: Predictors of TIMI ≤ 3 coronary flow after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 35:20A, 2000.
31. Grines CL, Browne KF, Marco J, et al: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 328:673-679, 1993.
32. GUSTO-IIb Angioplasty Substudy Investigators: A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 336:1621-1628, 1997.
33. Zijlstra F: Primary angioplasty is the most effective treatment for an acute myocardial infarction. Br Heart J 73:403-404, 1995.
34. White CJ, Ramee SR, Collins TJ, et al: Coronary thrombi increase PTCA risk. Circulation 93:253-258, 1996.
35. Saber RS, Edwards WD, Bailey KR, et al: Coronary embolization after balloon angioplasty or thrombolytic therapy: An autopsy study of 32 cases. J Am Coll Cardiol 22:1283-1288, 1993.
36. Rashdan I, Schechter E: Safety and efficacy in abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty. Cathet Cardiovasc Intervent 49:113-116, 2000.
37. Siegel RJ, Steffen W, Cumberland DC: Ultrasound angioplasty. In: Textbook of Interventional Cardiology, ed. by Topol EJ. Philadelphia: WB Saunders, 1958, pp 635-649.
38. Rosenschein U, Frimerman A, Laniado S, et al: Study of the mechanism of ultrasound angioplasty from human thrombi and bovine aorta. Am J Cardiol 24:1263-1266, 1994.
39. Rosenschein U, Rozenszajn LA, Kraus L, et al: Ultrasonic angioplasty in totally occluded peripheral arteries: Initial clinical, histopathologic and angiographic results. Circulation 83:1976-1986, 1991.
40. Rosenschein U, Gaul G, Erbel R, et al: Percutaneous transluminal therapy of occluded saphenous vein grafts. Circulation 99:26-29, 1999.
41. Rosenchein U, Roth A, Rassin T, et al: Analysis of coronary ultrasound thrombolysis: End points in acute myocardial infarction (ACUTE trial). Circulation 95:1411-1416, 1997.
42. Rosenschein U, Furman V, Kerner E, et al: Ultrasound imaging-guided noninvasive ultrasound thrombolysis. Circulation 102:238-245, 2000.
43. Topaz O: Laser. In: Textbook of Interventional Cardiology, ed. 4, ed. by Topol EJ. Philadelphia: WB Saunders, 2002, pp 675-703.
44. Bittl JA, Brinker JA, Sanborn TA, et al: The changing profile of patient selection, procedural techniques and outcomes in excimer laser coronary angioplasty. J Intervent Cardiol 8:654-660, 1995.
45. Topaz O, McIvor M, Stone GW, et al: Acute results, complications and effect of lesion characteristics on outcome with solid-state, pulsed-wave, mid-infrared laser angioplasty system: Final multicenter report. Laser Surg Med 22:228-239, 1998.
46. Biamino GC, Ragg JC, Struk B, et al: Long occlusions of the superficial femoral artery: Success rate and 1-year follow-up after excimer laser-assisted angioplasty. Eur Heart J 15:(suppl 1):147, 1994.
47. Topaz O, Morris C, Minisi AJ, et al: Enhancement of t-PA-induced fibrinolysis with laser energy: In-vitro observations. Laser Med Sci 14:123-128, 1999.
48. Topaz O, Rozenbaum EA, Schumacker A, et al: Solid-state, mid-infrared laser-facilitated coronary angioplasty: Clinical and quantitative angiographic results in 112 patients. Laser Surg Med 19:260-272, 1996.
49. Topaz O, Bernardo NL, McQueen RA, et al: Effectiveness of excimer laser coronary angioplasty in acute myocardial infarction or in unstable angina pectoris. Am J Cardiol 87:849-855, 2001.
50. Topaz O, Shah R, Mohanty PK, et al: Application of excimer laser angioplasty in acute myocardial infarction. Lasers Surg Med 29:185-192, 2001.
51. Dahm JB, Topaz O, Woenckhaus C, et al: Laser-facilitated thrombectomy: A new therapeutic option for treatment of thrombus-laden coronary lesions. Cathet Cardiovasc Intervent 56:365-372, 2002.
52. Topaz O, Minisi AJ, Luxenberg MG, et al: Laser angioplasty for lesions unsuitable for PTCA in acute myocardial infarction: Quantitative coronary angiography and clinical results. Circulation 90(suppl I): 1-434, 1994.
53. Gregory KW: Laser thrombolysis. In: Textbook of Interventional Cardiology, ed. 2, ed. by Topol EJ. Philadelphia: WB Saunders, 1993, pp 892-902.
54. Gregory KW, Flotte T, Michand N: Laser-induced inhibition of platelet adhesion. Circulation 80(suppl II):II-523, 1989.
55. Topaz O, Minisi AJ, Bernardo NL, et al: Alterations of platelet aggregation kinetics with ultraviolet laser emission: The "stunned platelets" phenomenon. Thromb Haemost 86:1087-1093, 2001.
56. Topaz O, Minisi AJ, Morris C, et al: Photoacoustic fibrinolysis: Pulsed wave, midinfrared, laser clot interaction. J Thromb Thrombol 3:209-214, 1996.
57. Safian RD: Coronary atherectomy: Directional and extraction techniques. In: Textbook of Interventional Cardiology, ed. 3, ed. by Topol EJ. Philadelphia: WB Saunders, 1998, pp 501-522.
58. Topaz O, Bernardo N, Desai P, et al: Acute thrombotic-ischemic syndromes: The usefulness of TEC. Cathet Cardiovasc Intervent 48:406-420, 1999.
59. Sullebarger JT, Dalton RD, Nasser A, et al: Adjunct abciximab improves outcomes during recanalization of totally occluded saphenous vein grafts using TEC. Cathet Cardiovasc Intervent 46:107-110, 1999.
60. Kim RH, Fischman DL, Dempsey CM, et al: Rheolytic thrombectomy of chronic coronary occlusion. Cathet Cardiovasc Diagn 43:483-489, 1998.
61. Scott LRP, Silva JA, White C, et al: Rheolytic thrombectomy: A new treatment for stent thrombosis. Cathet Cardiovasc Intervent 47:97-101, 1999.
62. Nakagawa Y, Matsuo S, Yukoi H, et al: Stenting after thrombectomy with the Angiojet catheter for acute myocardial infarction. Cathet Cardiovasc Diagn 43:327-330, 1998.
63. Singh M, Tiede DJ, Mathew V, et al: Rheolytic thrombectomy with Angiojet in thrombus-containing lesions. Cathet Cardiovasc Intervent 56:1-7, 2002.
64. Dohad S, Parris TM, Setum C, et al: Angiojet rheolytic thrombectomy: An important tool for percutaneous coronary interventions in high-risk patients: VEGAS II trial. J Am Coll Cardiol 35(suppl A):75A, 2000.
65. Nishida T, Nakamura M, Tsunda T, et al: A case of acute myocardial infarction treated with a new thrombectomy system. Cathet Cardiovasc Intervent 55:239-243, 2002.
66. Kwok OH, Prpic R, Gaspar J, et al: Angiographic outcome after intracoronary X-Sizer helical atherectomy and thrombectomy: First use in humans. Cathet Cardiovasc Intervent 55:133-139, 2002.
67. Ischinger T: Thrombectomy with the X-Sizer catheter system in the coronary circulation: Initial results from a multi-center study. J Invas Cardiol 13:81-88, 2001.
68. Sanmartin M, Goicolea J, Salmeron-Ruiz R, et al: Coronary perforation as a potential complication derived from coronary thrombectomy with the X-Sizer device. Cathet Cardiovasc Intervent 56:378-382, 2002.